Centessa Pharmaceuticals plc
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $15.0M
- Net income
- -$197.5M
- Total assets
- $687.5M
- Market cap
- $6.1B
- Operating margin
- -1384.6%
- Net margin
- -1316.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $15.0M
- Operating expenses
- $222.7M
- Operating income
- -$207.7M
- Income tax
- $1.8M
- Net income
- -$197.5M
- EPS (basic)
- $-1.46
- EPS (diluted)
- $-1.46
Balance sheet
- Total assets
- $687.5M
- Current assets
- $367.9M
- Total liabilities
- $160.6M
- Current liabilities
- $42.9M
- Shareholders’ equity
- $526.9M
Cash flow
- Operating cash flow
- -$193.8M
- Investing cash flow
- -$418.5M
- Financing cash flow
- $291.5M
- Net cash flow
- -$321.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.1B
- EPS (diluted)
- $-1.46
- Shares outstanding
- 154.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 28, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $197.5M in FY2025.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Centessa Pharmaceuticals plc.
Write a review
News about Centessa Pharmaceuticals plc
News & sentiment via Polygon.io
